These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29222257)

  • 21. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
    Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
    Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
    Rawstron AC; Paiva B; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
    Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
    J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular detection of minimal residual disease in multiple myeloma.
    Bai Y; Orfao A; Chim CS
    Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease analysis in myeloma - when, why and where.
    Yanamandra U; Kumar SK
    Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
    Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
    J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.
    Avet-Loiseau H
    Am Soc Clin Oncol Educ Book; 2016; 35():e425-30. PubMed ID: 27249750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
    Kim HY; Yoo IY; Lim DJ; Kim HJ; Kim SH; Yoon SE; Kim SJ; Cho D; Kim K
    Ann Lab Med; 2022 Sep; 42(5):558-565. PubMed ID: 35470273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari S; Hillengass J; McCarthy PL; Holstein SA
    Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic significance of sequencing-based MRD detection in multiple myeloma].
    Takamatsu H
    Rinsho Ketsueki; 2015 Aug; 56(8):989-96. PubMed ID: 26345557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple Myeloma Minimal Residual Disease.
    Paiva B; García-Sanz R; San Miguel JF
    Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
    Paiva B; van Dongen JJ; Orfao A
    Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
    Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
    Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
    Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
    Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
    Bertuglia G; Cani L; Larocca A; Gay F; D'Agostino M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
    Gormley NJ; Turley DM; Dickey JS; Farrell AT; Reaman GH; Stafford E; Carrington L; Marti GE
    Cytometry B Clin Cytom; 2016 Jan; 90(1):73-80. PubMed ID: 26108351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
    Fonseca R; Arribas M; Wiedmeier-Nutor JE; Kusne YN; González Vélez M; Kosiorek HE; Butterfield RDJ; Kirsch IR; Mikhael JR; Stewart AK; Reeder C; Larsen J; Bergsagel PL; Fonseca R
    Blood Cancer J; 2023 Mar; 13(1):32. PubMed ID: 36878906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
    Rawstron AC; Orfao A; Beksac M; Bezdickova L; Brooimans RA; Bumbea H; Dalva K; Fuhler G; Gratama J; Hose D; Kovarova L; Lioznov M; Mateo G; Morilla R; Mylin AK; Omedé P; Pellat-Deceunynck C; Perez Andres M; Petrucci M; Ruggeri M; Rymkiewicz G; Schmitz A; Schreder M; Seynaeve C; Spacek M; de Tute RM; Van Valckenborgh E; Weston-Bell N; Owen RG; San Miguel JF; Sonneveld P; Johnsen HE;
    Haematologica; 2008 Mar; 93(3):431-8. PubMed ID: 18268286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
    Bal S; Costa LJ
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.